Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
| ▸ | PPARD | Q03181 | 6/20 | 0.50 |
| ▸ | PPARA | Q07869 | 6/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14332654 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL11678561 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL22309883 | 0.92 | SLC22A6 (0.61) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4811015 | 0.89 | HDAC3 (0.43) | TSHRLMNANFKB1PMP22GPR84 | |
| Octanedioate SCHEMBL28415097 | 0.83 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL7086929 | 0.80 | — | — | |
| SCHEMBL25186232 | 0.80 | TSHR (1.00) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL1674812 | 0.80 | TSHR (1.00) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL166746 | 0.80 | TSHR (1.00) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL21065467 | 0.80 | TSHR (1.00) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7344851-B2 | Anticancer agents based on prevention of protein prenylation | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2008-03-18 | — | — | US | disclosed |
| US-7012097-B2 | Anticancer agents based on prevention of protein prenylation | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2006-03-14 | — | — | US | disclosed |
| US-20060030624-A1 | Alpha-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase; drug screening; antitumor agents; antiproliferative agents | ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2006-02-09 | — | — | US | disclosed |
| US-20030219847-A1 | Anticancer agents based on prevention of protein prenylation | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION | 2003-11-27 | — | — | US | disclosed |
| US-6576436-B1 | Inactivating farnesyltransferase using a alpha-dicarbonyl compound of given formula; drug screening; antitumor agents; antiproliferative agents | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION | 2003-06-10 | — | — | US | disclosed |
| WO-2000033826-A1 | ANTICANCER AGENTS BASED ON PREVENTION OF PROTEIN PRENYLATION | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219847-A1 | Anticancer agents based on prevention of protein prenylation | RCE1, FNTA, FNTB | TSHR 4367/4885LMNA 2521/4885NFKB1 2343/4885 |
| US-20060030624-A1 | Alpha-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase; drug screening; antitumor agents; antiproliferative agents | FNTA, FNTB, RCE1 | TSHR 4052/4885LMNA 1593/4885NFKB1 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.